A novel strategy for efficient production of anti-V3 human scFvs against HIV-1 clade C
详细信息 查看全文
- 作者：Rajesh Kumar (1)
Raiees Andrabi (1)
Ashutosh Tiwari (1) (4)
Somi Sankaran Prakash (1)
Naveet Wig (2)
Durgashree Dutta (1)
Anurag Sankhyan (1)
Lubina Khan (1)
Subrata Sinha (1) (3)
Kalpana Luthra (1) - 关键词：HIV ; 1 ; Clade C ; V3 ; scFv
- 刊名：BMC Biotechnology
- 出版年：2012
- 出版时间：December 2012
- 年：2012
- 卷：12
- 期：1
- 全文大小：473KB
- 参考文献：1. Moulard M, Phogat SK, Shu Y, Labrijn AF, Xiao X, Binley JM, Zhang M-Y, Sidorov IA, Broder CC, Robinson J, Parren PWHI, Burton DR, Dimitrov DS: Broadly cross-reactive HIV-1-neutralizing human monoclonal Fab selected for binding to gp120-CD4-CCR5 complexes. / Proc Natl Acad Sci USA 2002, 99:6913鈥?918. CrossRef
2. Zolla-Pazner S, Zhong P, Revesz K, Volsky B, Williams C, Nyambi P, Gorny MK: The cross-clade neutralizing activity of a human monoclonal antibody is determined by the GPGR V3 motif of HIV type 1. / AIDS Res Hum Retroviruses 2004, 20:1254鈥?258. CrossRef
3. Burton DR, Pyati J, Koduri R, Sharp SJ, Thornton GB, Parren PW, Sawyer LS, Hendry RM, Dunlop N, Nara PL: Efficient neutralization of primary isolates of HIV-1 by a recombinant human monoclonal antibody. / Science 1994, 266:1024鈥?027. CrossRef
4. Gorny MK, Williams C, Volsky B, Revesz K, Wang X-H, Burda S, Kimura T, Konings FAJ, N谩das A, Anyangwe CA, Nyambi P, Krachmarov C, Pinter A, Zolla-Pazner S: Cross-clade neutralizing activity of human anti-V3 monoclonal antibodies derived from the cells of individuals infected with non-B clades of human immunodeficiency virus type 1. / J Virol 2006, 80:6865鈥?872. CrossRef
5. Pantophlet R, Ollmann Saphire E, Poignard P, Parren PWHI, Wilson IA, Burton DR: Fine mapping of the interaction of neutralizing and nonneutralizing monoclonal antibodies with the CD4 binding site of human immunodeficiency virus type 1 gp120. / J Virol 2003, 77:642鈥?58. CrossRef
6. Posner MR, Hideshima T, Cannon T, Mukherjee M, Mayer KH, Byrn RA: An IgG human monoclonal antibody that reacts with HIV-1/GP120, inhibits virus binding to cells, and neutralizes infection. / J Immunol 1991, 146:4325鈥?332.
7. Trkola A, Dragic T, Arthos J, Binley JM, Olson WC, Allaway GP, Cheng-Mayer C, Robinson J, Maddon PJ, Moore JP: CD4-dependent, antibody-sensitive interactions between HIV-1 and its co-receptor CCR-5. / Nature 1996, 384:184鈥?87. CrossRef
8. Scheid JF, Mouquet H, Feldhahn N, Seaman MS, Velinzon K, Pietzsch J, Ott RG, Anthony RM, Zebroski H, Hurley A, Phogat A, Chakrabarti B, Li Y, Connors M, Pereyra F, Walker BD, Wardemann H, Ho D, Wyatt RT, Mascola JR, Ravetch JV, Nussenzweig MC: Broad diversity of neutralizing antibodies isolated from memory B cells in HIV-infected individuals. / Nature 2009, 458:636鈥?40. CrossRef
9. Walker LM, Phogat SK, Chan-Hui P-Y, Wagner D, Phung P, Goss JL, Wrin T, Simek MD, Fling S, Mitcham JL, Lehrman JK, Priddy FH, Olsen OA, Frey SM, Hammond PW, Kaminsky S, Zamb T, Moyle M, Koff WC, Poignard P, Burton DR: Broad and potent neutralizing antibodies from an African donor reveal a new HIV-1 vaccine target. / Science 2009, 326:285鈥?89. CrossRef
10. Wu X, Yang Z-Y, Li Y, Hogerkorp C-M, Schief WR, Seaman MS, Zhou T, Schmidt SD, Wu L, Xu L, Longo NS, McKee K, O鈥橠ell S, Louder MK, Wycuff DL, Feng Y, Nason M, Doria-Rose N, Connors M, Kwong PD, Roederer M, Wyatt RT, Nabel GJ, Mascola JR: Rational design of envelope identifies broadly neutralizing human monoclonal antibodies to HIV-1. / Science 2010, 329:856鈥?61. CrossRef
11. Gray ES, Meyers T, Gray G, Montefiori DC, Morris L: Insensitivity of paediatric HIV-1 subtype C viruses to broadly neutralising monoclonal antibodies raised against subtype B. / PLoS Med 2006, 3:e255. CrossRef
12. Moore PL, Gray ES, Sheward D, Madiga M, Ranchobe N, Lai Z, Honnen WJ, Nonyane M, Tumba N, Hermanus T, Sibeko S, Mlisana K, Abdool Karim SS, Williamson C, Pinter A, Morris L: Potent and broad neutralization of HIV-1 subtype C by plasma antibodies targeting a quaternary epitope including residues in the V2 loop. / J Virol 2011, 85:3128鈥?141. CrossRef
13. Gorny MK, Gianakakos V, Sharpe S, Zolla-Pazner S: Generation of human monoclonal antibodies to human immunodeficiency virus. / Proc Natl Acad Sci USA 1989, 86:1624鈥?628. CrossRef
14. Smith GP: Filamentous fusion phage: novel expression vectors that display cloned antigens on the virion surface. / Science 1985, 228:1315鈥?317. CrossRef
15. Pansri P, Jaruseranee N, Rangnoi K, Kristensen P, Yamabhai M: A compact phage display human scFv library for selection of antibodies to a wide variety of antigens. / BMC Biotechnol 2009, 9:6. CrossRef
16. Winter G, Griffiths AD, Hawkins RE, Hoogenboom HR: Making antibodies by phage display technology. / Annu Rev Immunol 1994, 12:433鈥?55. CrossRef
17. Bugli F, Graffeo R, Paroni Sterbini F, Torelli R, Masucci L, Sali M, Grasso A, Rufini S, Ricci E, Fadda G, Pescatori M: Monoclonal antibody fragment from combinatorial phage display library neutralizes alpha-latrotoxin activity and abolishes black widow spider venom lethality, in mice. / Toxicon 2008, 51:547鈥?54. CrossRef
18. Andre F, Fr枚de D, Meyer T, Schirrmann T, Hust M: Generating Recombinant Antibodies for Research, Diagnostics and Therapy Using Phage Display. / Current Biotechnology 2012, 1:33鈥?1. CrossRef
19. Kuwata T, Katsumata Y, Takaki K, Miura T, Igarashi T: Isolation of potent neutralizing monoclonal antibodies from an SIV-Infected rhesus macaque by phage display. / AIDS Res Hum Retroviruses 2011, 27:487鈥?00.
20. Kempf E, Weiss E, Klein P, Glacet A, Spratt S, Bourel D, Orfanoudakis G: The rescue by phage display of human Fabs to gp120 HIV-1 glycoprotein using EBV transformed lymphocytes. / Mol Biotechnol 2001, 17:97鈥?08. CrossRef
21. Hemelaar J, Gouws E, Ghys PD, Osmanov S: Global and regional distribution of HIV-1 genetic subtypes and recombinants in 2004. / AIDS 2006, 20:W13-W23. CrossRef
22. Cardozo T, Kimura T, Philpott S, Weiser B, Burger H, Zolla-Pazner S: Structural basis for coreceptor selectivity by the HIV type 1 V3 loop. / AIDS Res Hum Retroviruses 2007, 23:415鈥?26. CrossRef
23. Sharon M, Kessler N, Levy R, Zolla-Pazner S, G枚rlach M, Anglister J: Alternative conformations of HIV-1 V3 loops mimic beta hairpins in chemokines, suggesting a mechanism for coreceptor selectivity. / Structure 2003, 11:225鈥?36. CrossRef
24. Hill CM, Deng H, Unutmaz D, Kewalramani VN, Bastiani L, Gorny MK, Zolla-Pazner S, Littman DR: Envelope glycoproteins from human immunodeficiency virus types 1 and 2 and simian immunodeficiency virus can use human CCR5 as a coreceptor for viral entry and make direct CD4-dependent interactions with this chemokine receptor. / J Virol 1997, 71:6296鈥?304.
25. Wang WK, Dudek T, Essex M, Lee TH: Hypervariable region 3 residues of HIV type 1 gp120 involved in CCR5 coreceptor utilization: therapeutic and prophylactic implications. / Proc Natl Acad Sci USA 1999, 96:4558鈥?562. CrossRef
26. Andrabi R, Choudhary AK, Bala M, Kalra R, Prakash SS, Pandey RM, Luthra K: Relative reactivity of HIV-1 polyclonal plasma antibodies directed to V3 and MPER regions suggests immunodominance of V3 over MPER and dependence of high anti-V3 antibody titers on virus persistence. / Arch Virol 2011, 156:1787鈥?794. CrossRef
27. Andrabi R, Bala M, Kumar R, Wig N, Hazarika A, Luthra K: Neutralization of tier-2 viruses and epitope profiling of plasma antibodies from human immunodeficiency virus type 1 infected donors from India. / PLoS One 2012, 7:e43704. CrossRef
28. Krebber A, Bornhauser S, Burmester J, Honegger A, Willuda J, Bosshard HR, Pl眉ckthun A: Reliable cloning of functional antibody variable domains from hybridomas and spleen cell repertoires employing a reengineered phage display system. / J Immunol Methods 1997, 201:35鈥?5. CrossRef
29. Gorny MK, Sampson J, Li H, Jiang X, Totrov M, Wang X-H, Williams C, O鈥橬eal T, Volsky B, Li L, Cardozo T, Nyambi P, Zolla-Pazner S, Kong X-P: Human anti-V3 HIV-1 monoclonal antibodies encoded by the VH5鈥?1/VL lambda genes define a conserved antigenic structure. / PLoS One 2011, 6:e27780. CrossRef
30. David D, Goossens D, Desgranges C, Th猫ze J, Zouali M: Molecular characterization of human monoclonal antibodies specific for several HIV proteins: analysis of the VH3 family expression. / Immunol Lett 1995, 47:107鈥?12. CrossRef
31. Wisnewski A, Cavacini L, Posner M: Human antibody variable region gene usage in HIV-1 infection. / J Acquir Immune Defic Syndr Hum Retrovirol 1996, 11:31鈥?8. CrossRef
32. Chahboun S, Hust M, Liu Y, Pelat T, Miethe S, Helmsing S, Jones RG, Sesardic D, Thullier P: Isolation of a nanomolar scFv inhibiting the endopeptidase activity of botulinum toxin A, by single-round panning of an immune phage-displayed library of macaque origin. / BMC Biotechnol 2011, 11:113. CrossRef
33. Burmester J, Spinelli S, Pugliese L, Krebber A, Honegger A, Jung S, Schimmele B, Cambillau C, Pl眉ckthun A: Selection, characterization and x-ray structure of anti-ampicillin single-chain Fv fragments from phage-displayed murine antibody libraries. / J Mol Biol 2001, 309:671鈥?85. CrossRef
34. Rangnoi K, Jaruseranee N, O鈥橩ennedy R, Pansri P, Yamabhai M: One-step detection of aflatoxin-B(1) using scFv-alkaline phosphatase-fusion selected from human phage display antibody library. / Mol Biotechnol 2011, 49:240鈥?49. CrossRef
35. Little M, Welschof M, Braunagel M, Hermes I, Christ C, Keller A, Rohrbach P, K眉rschner T, Schmidt S, Kleist C, Terness P: Generation of a large complex antibody library from multiple donors. / J Immunol Methods 1999, 231:3鈥?. CrossRef
36. Okamoto T, Mukai Y, Yoshioka Y, Shibata H, Kawamura M, Yamamoto Y, Nakagawa S, Kamada H, Hayakawa T, Mayumi T, Tsutsumi Y: Optimal construction of non-immune scFv phage display libraries from mouse bone marrow and spleen established to select specific scFvs efficiently binding to antigen. / Biochem Biophys Res Commun 2004, 323:583鈥?91. CrossRef
37. Vaughan TJ, Williams AJ, Pritchard K, Osbourn JK, Pope AR, Earnshaw JC, McCafferty J, Hodits RA, Wilton J, Johnson KS: Human antibodies with sub-nanomolar affinities isolated from a large non-immunized phage display library. / Nat Biotechnol 1996, 14:309鈥?14. CrossRef
38. Bose B, Chugh DA, Kala M, Acharya SK, Khanna N, Sinha S: Characterization and molecular modeling of a highly stable anti-Hepatitis B surface antigen scFv. / Mol Immunol 2003, 40:617鈥?31. CrossRef
39. Zhang MY, Shu Y, Rudolph D, Prabakaran P, Labrijn AF, Zwick MB, Lal RB, Dimitrov DS: Improved breadth and potency of an HIV-1-neutralizing human single-chain antibody by random mutagenesis and sequential antigen panning. / J Mol Biol 2004, 335:209鈥?19. CrossRef
40. Montefiori DC: Measuring HIV neutralization in a luciferase reporter gene assay. / Methods Mol Biol 2009, 485:395鈥?05. CrossRef
41. Seaman MS, Janes H, Hawkins N, Grandpre LE, Devoy C, Giri A, Coffey RT, Harris L, Wood B, Daniels MG, Bhattacharya T, Lapedes A, Polonis VR, McCutchan FE, Gilbert PB, Self SG, Korber BT, Montefiori DC, Mascola JR: Tiered categorization of a diverse panel of HIV-1 Env pseudoviruses for assessment of neutralizing antibodies. / J Virol 2010, 84:1439鈥?452. CrossRef
42. Tiwari A, Khanna N, Acharya SK, Sinha S: Humanization of high affinity anti-HBs antibody by using human consensus sequence and modification of selected minimal positional template and packing residues. / Vaccine 2009, 27:2356鈥?366. CrossRef
43. Caputo JL, Thompson A, McClintock P, Reid YA, Hay RJ: An effective method for establishing human B lymphoblastic cell lines using epstein-barr virus. / Methods Cell Sci 1991, 13:39鈥?4.
44. Traggiai E, Becker S, Subbarao K, Kolesnikova L, Uematsu Y, Gismondo MR, Murphy BR, Rappuoli R, Lanzavecchia A: An efficient method to make human monoclonal antibodies from memory B cells: potent neutralization of SARS coronavirus. / Nat Med 2004, 10:871鈥?75. CrossRef
45. NCBI: / Ig BLAST. http://www.ncbi.nlm.nih.gov/igblast/
46. Althaus H-H, M眉ller W, Tomlinson I: / V BASE. http://vbase.mrccpe.cam.ac.uk/ - 作者单位：Rajesh Kumar (1)
Raiees Andrabi (1)
Ashutosh Tiwari (1) (4)
Somi Sankaran Prakash (1)
Naveet Wig (2)
Durgashree Dutta (1)
Anurag Sankhyan (1)
Lubina Khan (1)
Subrata Sinha (1) (3)
Kalpana Luthra (1)
1. Department of Biochemistry, All India Institute of Medical Sciences, New Delhi, India
4. Centre for Biodesign, Translational Health Science and Technology Institute, Gurgaon, India
2. Department of Medicine, All India Institute of Medical Sciences, New Delhi, India
3. National Brain Research Centre, Manesar, India - ISSN：1472-6750
文摘
Background Production of human monoclonal antibodies that exhibit broadly neutralizing activity is needed for preventing HIV-1 infection, however only a few such antibodies have been generated till date. Isolation of antibodies by the hybridoma technology is a cumbersome process with fewer yields. Further, the loss of unstable or slowly growing clones which may have unique binding specificities often occurs during cloning and propagation and the strongly positive clones are often lost. This has been avoided by the process described in this paper, wherein, by combining the strategy of EBV transformation and recombinant DNA technology, we constructed human single chain variable fragments (scFvs) against the third variable region (V3) of the clade C HIV-1 envelope. Results An antigen specific phage library of 7000 clones was constructed from the enriched V3- positive antibody secreting EBV transformed cells. By ligation of the digested scFv DNA into phagemid vector and bio panning against the HIV-1 consensus C and B V3 peptides followed by random selection of 40 clones, we identified 15 clones that showed V3 reactivity in phage ELISA. DNA fingerprinting analysis and sequencing showed that 13 out of the 15 clones were distinct. Expression of the positive clones was tested by SDS-PAGE and Western blot. All the 13 anti-V3 scFvs showed cross-reactivity against both the clade C and B V3 peptides and did not show any reactivity against other unrelated peptides in ELISA. Preliminary neutralization assays indicated varying degrees of neutralization of clade C and B viruses. EBV transformation, followed by antigen selection of lines to identify specific binders, enabled the selection of phage from un-cloned lines for scFv generation, thus avoiding the problems of hybridoma technology. Moreover, as the clones were pretested for antigen binding, a comparatively small library sufficed for the selection of a considerable number of unique antigen binding phage. After selection, the phage clones were propagated in a clonal manner. Conclusions This strategy can be efficiently used and is cost effective for the generation of diverse recombinant antibodies. This is the first study to generate anti-V3 scFvs against HIV-1 Clade C.